{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:56Z","timestamp":1791972776859,"version":"4.3.4"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.hoc.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T23:03:00Z","timestamp":1663887780000},"page":"1033-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genetics of Pancreatic Neuroendocrine Tumors"],"prefix":"10.1016","volume":"36","author":[{"given":"Chirayu","family":"Mohindroo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1038\/modpathol.3800686","article-title":"Nonductal neoplasms of the pancreas","volume":"20","author":"Klimstra","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hoc.2022.07.005_bib4","series-title":"WHO classification of tumours of the digestive system","author":"Bosman","year":"2010"},{"key":"10.1016\/j.hoc.2022.07.005_bib5","series-title":"WHO classification of tumours of endocrine organs","author":"Weltgesundheitsorganisation","year":"2017"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1210\/er.2003-0037","article-title":"Hereditary hormone excess: genes, molecular pathways, and syndromes","volume":"26","author":"Marx","year":"2005","journal-title":"Endocr Rev"},{"issue":"7643","key":"10.1016\/j.hoc.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"6021","key":"10.1016\/j.hoc.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5858\/133.3.350","article-title":"Endocrine neoplasms of the pancreas: pathologic and genetic features","volume":"133","author":"Capelli","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1677\/ERC-10-0028","article-title":"MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases","volume":"17","author":"Corbo","year":"2010","journal-title":"Endocr Relat cancer"},{"issue":"8","key":"10.1016\/j.hoc.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.3390\/ijms22084041","article-title":"Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1","volume":"22","author":"Marini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"41","key":"10.1016\/j.hoc.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"14659","DOI":"10.1073\/pnas.0503484102","article-title":"Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c","volume":"102","author":"Karnik","year":"2005","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1677\/erc.1.01220","article-title":"Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study","volume":"13","author":"Kann","year":"2006","journal-title":"Endocr Relat cancer"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/0008-5472.CAN-08-3662","article-title":"Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1","volume":"69","author":"Shen","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2022.07.005_bib16","first-page":"1","article-title":"Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability","volume":"2","author":"Raj","year":"2018","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.hoc.2022.07.005_bib17","doi-asserted-by":"crossref","unstructured":"Elsaesser S, Allis C. HIRA and Daxx constitute two independent histone H3. 3-containing predeposition complexes. Paper presented at: Cold Spring Harbor symposia on quantitative biology2010.","DOI":"10.1101\/sqb.2010.75.008"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cell.2010.01.003","article-title":"Distinct factors control histone variant H3. 3 localization at specific genomic regions","volume":"140","author":"Goldberg","year":"2010","journal-title":"Cell"},{"issue":"32","key":"10.1016\/j.hoc.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"14075","DOI":"10.1073\/pnas.1008850107","article-title":"Daxx is an H3. 3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres","volume":"107","author":"Lewis","year":"2010","journal-title":"Proc Natl Acad Sci"},{"issue":"6041","key":"10.1016\/j.hoc.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.hoc.2022.07.005_bib22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/modpathol.2012.53","article-title":"Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors","volume":"25","author":"De Wilde","year":"2012","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","article-title":"PI3K and mTOR signaling pathways in cancer: new data on targeted therapies","volume":"14","author":"Willems","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2022.07.005_bib25","first-page":"719","article-title":"Prognostic Significance of Altered ATRX\/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","article-title":"Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases","volume":"38","author":"Basturk","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"16","key":"10.1016\/j.hoc.2022.07.005_bib27","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2016.217","article-title":"Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20","volume":"30","author":"Konukiewitz","year":"2017","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.7150\/ijbs.9773","article-title":"KRAS and DAXX\/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors","volume":"10","author":"Yuan","year":"2014","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib32","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","article-title":"Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.hoc.2022.07.005_bib33","doi-asserted-by":"crossref","first-page":"49796","DOI":"10.18632\/oncotarget.17964","article-title":"DAXX\/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2022.07.005_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.humpath.2018.07.032","article-title":"ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors","volume":"82","author":"Chou","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib35","first-page":"1","article-title":"DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2019","journal-title":"Scientific Rep"},{"issue":"8","key":"10.1016\/j.hoc.2022.07.005_bib36","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1053\/j.gastro.2018.02.026","article-title":"Loss of chromatin-remodeling proteins and\/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times","volume":"154","author":"Roy","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2022.07.005_bib39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: Efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3810","article-title":"Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1","volume":"4","author":"Cao","year":"2013","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.hoc.2022.07.005_bib42","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1073\/pnas.1503696112","article-title":"Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas","volume":"112","author":"Cromer","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib43","doi-asserted-by":"crossref","first-page":"L31","DOI":"10.1530\/ERC-17-0311","article-title":"Frequency and consequence of the recurrent YY1 p. T372R mutation in sporadic insulinomas","volume":"25","author":"Parekh","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.hoc.2022.07.005_bib44","article-title":"Neuroendocrine Tumors Are Enriched in Cowden Syndrome","volume":"4","author":"Greidinger","year":"2020","journal-title":"JCO precision Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1210\/jc.2015-3684","article-title":"Neuroendocrine tumor of the pancreas as a manifestation of Cowden syndrome: a case report","volume":"101","author":"Neychev","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"S7","key":"10.1016\/j.hoc.2022.07.005_bib46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cncr.23648","article-title":"Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies","volume":"113","author":"Jensen","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/EJE-14-0878","article-title":"Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'\u00e9tude des Tumeurs Endocrines (GTE) retrospective study","volume":"172","author":"Vezzosi","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00428-007-0450-3","article-title":"Hereditary neuroendocrine tumors of the gastroenteropancreatic system","volume":"451","author":"Anlauf","year":"2007","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.hoc.2022.07.005_bib49","series-title":"Distinct prognostic factors in sporadic and multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors","author":"Kfir","year":"2021"},{"key":"10.1016\/j.hoc.2022.07.005_bib50","unstructured":"Ahmed F.W., Majeed M.S., Kirresh O., Multiple Endocrine Neoplasias Type 4. [Updated 2022 Apr 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568728\/"},{"key":"10.1016\/j.hoc.2022.07.005_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.6061\/clinics\/2012(Sup01)04","article-title":"MENX and MEN4","volume":"67","author":"Pellegata","year":"2012","journal-title":"Clinics"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2022.07.005_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2013.08.002","article-title":"Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)","volume":"386","author":"Thakker","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.hoc.2022.07.005_bib53","doi-asserted-by":"crossref","first-page":"T195","DOI":"10.1530\/ERC-17-0243","article-title":"MEN4 and CDKN1B mutations: the latest of the MEN syndromes","volume":"24","author":"Alrezk","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2022.07.005_bib54","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Francis","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib55","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2019-00082","article-title":"Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases","volume":"104","author":"Frederiksen","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.hoc.2022.07.005_bib56","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1210\/jc.2006-2843","article-title":"Germline CDKN1B\/p27Kip1 mutation in multiple endocrine neoplasia","volume":"92","author":"Georgitsi","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib57","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib58","first-page":"116","article-title":"Hereditary Cancer Syndromes in Children: Von Hippel\u2013Lindau Disease","volume":"5","author":"Findeis-Hosey","year":"2016","journal-title":"J\u00a0Pediatr Genet"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/SLA.0000000000000856","article-title":"Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place","volume":"262","author":"de Mestier","year":"2015","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrclinonc.2016.37","article-title":"Evaluation and management of pancreatic lesions in patients with von Hippel\u2013Lindau disease","volume":"13","author":"Keutgen","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jamcollsurg.2013.10.025","article-title":"Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome","volume":"218","author":"Weisbrod","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/ERC-18-0100","article-title":"Preventive medicine of von Hippel\u2013Lindau disease-associated pancreatic neuroendocrine tumors","volume":"25","author":"Krauss","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib63","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1245\/s10434-012-2276-8","article-title":"Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel\u2013Lindau syndrome","volume":"19","author":"Weisbrod","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib64","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.surg.2007.09.012","article-title":"Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs)","volume":"142","author":"Blansfield","year":"2007","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.hoc.2022.07.005_bib65","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1007\/s11605-012-1847-0","article-title":"Pancreatic lesions in von Hippel\u2013Lindau disease? A systematic review and meta-synthesis of the literature","volume":"16","author":"Charlesworth","year":"2012","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00535-013-0794-1","article-title":"Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey","volume":"49","author":"Igarashi","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service","volume":"152","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib68","first-page":"6","article-title":"Multipoint linkage analysis in neurofibromatosis type I: an international collaboration","volume":"44","author":"Goldgar","year":"1989","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11154-017-9430-3","article-title":"When should genetic testing be performed in patients with neuroendocrine tumours?","volume":"18","author":"O\u2019Shea","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00428-007-0461-0","article-title":"Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors","volume":"451","author":"Kl\u00f6ppel","year":"2007","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.hoc.2022.07.005_bib72","unstructured":"Caiazzo R, Mariette C, Piessen G, Jany T, Carnaille B, Triboulet J. Type I neurofibromatosis, pheochromocytoma and somatostatinoma of the ampulla. Literature review. Paper presented at: Annales de chirurgie2006."},{"issue":"6355","key":"10.1016\/j.hoc.2022.07.005_bib73","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1136\/bmj.285.6355.1618","article-title":"Neurofibromatosis, phaeochromocytoma, and somatostatinoma","volume":"285","author":"Cantor","year":"1982","journal-title":"Br Med J (Clinical Res ed.)"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib74","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11605-009-1123-0","article-title":"Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases","volume":"14","author":"Relles","year":"2010","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00247-016-3701-0","article-title":"Pancreatic tumors in children and young adults with tuberous sclerosis complex","volume":"47","author":"Koc","year":"2017","journal-title":"Pediatr Radiol"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib76","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","article-title":"Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex","volume":"82","author":"Larson","year":"2012","journal-title":"Clin Genet"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib77","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/annonc\/mdx007","article-title":"Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation","volume":"28","author":"Schrader","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2022.07.005_bib78","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1055\/a-1186-0790","article-title":"Pancreatic neuroendocrine neoplasm associated with a familial MAX deletion","volume":"52","author":"Petignot","year":"2020","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06723-6","article-title":"The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report","volume":"20","author":"Aversa","year":"2020","journal-title":"BMC cancer"},{"issue":"10","key":"10.1016\/j.hoc.2022.07.005_bib81","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/jgo.2019.01.33","article-title":"The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors","volume":"10","author":"Nu\u00f1ez","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2022.07.005_bib83","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2022.07.005_bib84","unstructured":"Administration FaD. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. 2021; https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease. Accessed August 8, 2022."},{"issue":"22","key":"10.1016\/j.hoc.2022.07.005_bib85","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2022.07.005_bib86","unstructured":"Merck Sharp & Dohme LLC. Belzutifan\/MK-6482 for the Treatment of Advanced Pheochromocytoma\/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ClinicalTrials.gov identifier: NCT04924075. Updated July 14, 2022. Accessed August 8, 2022 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04924075"},{"issue":"7","key":"10.1016\/j.hoc.2022.07.005_bib87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib88","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/cen.13264","article-title":"Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours","volume":"86","author":"Donegan","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.sla.0000197715.96762.68","article-title":"Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas","volume":"243","author":"Triponez","year":"2006","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib92","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.hpb.2016.12.010","article-title":"Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors\u2013a systematic review and meta-analysis","volume":"19","author":"Sallinen","year":"2017","journal-title":"HPb"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/clinem\/dgz007","article-title":"Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors< 2 centimeters","volume":"105","author":"Faggiano","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.hoc.2022.07.005_bib94","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","article-title":"Von Hippel\u2013Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood","volume":"23","author":"Rednam","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/jamaoncol.2017.3428","article-title":"Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel\u2013Lindau disease","volume":"4","author":"Tirosh","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2022.07.005_bib96","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.1590\/0102-672020180001e1428","article-title":"Pancreatic neuroendocrine tumors: surgical resection","volume":"32","author":"Belotto","year":"2019","journal-title":"Arq Bras Cir Dig"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib97","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaoncol.2019.5963","article-title":"An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review","volume":"6","author":"Rainone","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib98","doi-asserted-by":"crossref","first-page":"R519","DOI":"10.1530\/ERC-19-0175","article-title":"The evolving (epi) genetic landscape of pancreatic neuroendocrine tumours","volume":"26","author":"Pipinikas","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10555-011-9290-3","article-title":"Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors","volume":"30","author":"Capdevila","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.hoc.2022.07.005_bib100","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijsu.2015.06.064","article-title":"Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it","volume":"21","author":"Capozzi","year":"2015","journal-title":"Int J Surg"},{"issue":"10022","key":"10.1016\/j.hoc.2022.07.005_bib101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib102","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat cancer"},{"issue":"3","key":"10.1016\/j.hoc.2022.07.005_bib103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"28","key":"10.1016\/j.hoc.2022.07.005_bib104","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2022.07.005_bib106","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9808","key":"10.1016\/j.hoc.2022.07.005_bib107","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2022.07.005_bib108","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2022.07.005_bib109","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.28726","article-title":"Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study","volume":"120","author":"Bajetta","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-11-0382","article-title":"Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors","volume":"19","author":"Chan","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib111","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/annonc\/mdx078","article-title":"A\u00a0randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2022.07.005_bib112","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2022.07.005_bib113","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.21873\/anticanres.11071","article-title":"Antiangiogenic therapy in pancreatic neuroendocrine tumors","volume":"36","author":"Capozzi","year":"2016","journal-title":"Anticancer Res"},{"issue":"18_suppl","key":"10.1016\/j.hoc.2022.07.005_bib114","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/jco.2007.25.18_suppl.4504","article-title":"MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study","volume":"25","author":"Hobday","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000456035","article-title":"Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments","volume":"105","author":"Angelousi","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"15","key":"10.1016\/j.hoc.2022.07.005_bib116","article-title":"Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+ B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance)","volume":"33","author":"Kulke","year":"2015","journal-title":"Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2022.07.005_bib117","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.28142","article-title":"A\u00a0prospective, phase 1\/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor","volume":"119","author":"Chan","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.07.005_bib118","first-page":"261","article-title":"NeuroEndocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): a phase I study","volume":"30","author":"Claringbold","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.hoc.2022.07.005_bib119","doi-asserted-by":"crossref","first-page":"e008248","DOI":"10.1136\/bmjopen-2015-008248","article-title":"Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial","volume":"5","author":"Neychev","year":"2015","journal-title":"BMJ open"},{"issue":"10","key":"10.1016\/j.hoc.2022.07.005_bib120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000448699","article-title":"Efficacy and long-term safety of everolimus in pancreatic neuroendocrine tumor associated with multiple endocrine neoplasia type I: case report","volume":"39","author":"Maia","year":"2016","journal-title":"Oncol Res Treat"},{"issue":"12","key":"10.1016\/j.hoc.2022.07.005_bib121","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.hoc.2022.07.005_bib122","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00268-004-7609-8","article-title":"Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors","volume":"28","author":"Dralle","year":"2004","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.hoc.2022.07.005_bib123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-10-0950","article-title":"Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines","volume":"165","author":"Goudet","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib124","first-page":"266","article-title":"Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1","volume":"101","author":"Thomas-Marques","year":"2006","journal-title":"J\u00a0Am Gastroenterol"},{"issue":"2","key":"10.1016\/j.hoc.2022.07.005_bib125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4158\/EP.8.2.109","article-title":"Insulinoma in a patient with tuberous sclerosis: is there an association?","volume":"8","author":"Eledrisi","year":"2002","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.hoc.2022.07.005_bib126","article-title":"Emerging value of multigene panels for germline testing in patients with neuroendocrine tumors","volume":"36","author":"Whitman","year":"2018","journal-title":"Am Soc Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:38Z","timestamp":1760185118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0889858822000739"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.07.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics of Pancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}